KSI-301 + Aflibercept
Phase 3Terminated 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Macular Edema
Conditions
Diabetic Macular Edema
Trial Timeline
Sep 30, 2020 → Aug 31, 2023
NCT ID
NCT04611152About KSI-301 + Aflibercept
KSI-301 + Aflibercept is a phase 3 stage product being developed by Kodiak Sciences for Diabetic Macular Edema. The current trial status is terminated. This product is registered under clinical trial identifier NCT04611152. Target conditions include Diabetic Macular Edema.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04964089 | Phase 3 | Completed |
| NCT04611152 | Phase 3 | Terminated |
| NCT04603937 | Phase 3 | Terminated |
| NCT04592419 | Phase 3 | Completed |
| NCT04049266 | Phase 2/3 | Terminated |
Competing Products
20 competing products in Diabetic Macular Edema